News | April 07, 2025
Sun Pharma introduces Fexuclue in India for treatment of Erosive Esophagitis
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
This investment is in addition to its first multi-billion-dollar project that was awarded to Fluor in 202
The portfolio includes branded injectable cephalosporines for infectious diseases
The Peptide Research Center is designed to support innovator pharma and biotech companies with specialized services across peptide synthesis, discovery, and advanced modalities, including complex conjugates
This collaboration positions WACKER and RNAV8 as premium mRNA service providers
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
The company expects to launch this product through its marketing partner in the near future
The IND application supports the next phase of development of SBO-154
New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle AD study
Subscribe To Our Newsletter & Stay Updated
